---
title: "A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease."
euct_id: 2024-516888-84-00
phase: Phase 3
status: Completed
sponsor: Arvinas Operations Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-516888-84-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-516888-84-00"
ctis_last_updated: "2025-12-25T02:33:21.127287952"
source: EU Clinical Trials Information System (CTIS)
---
# A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease.

**EU CT Number:** [2024-516888-84-00](https://euclinicaltrials.eu/ctis-public/view/2024-516888-84-00)

## Key Facts

- **Phase:** Phase 3
- **Status:** Completed
- **Sponsor:** Arvinas Operations Inc.
- **Start Date:** 2024-11-18
- **Completion Date:** 2026-02-01
- **Conditions:** Parkinson's disease.

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Centre for Human Drug Research, Leiden, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson's disease.
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-516888-84-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-516888-84-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-516888-84-00*